Synthon is a leading pharmaceutical company specialized in the development, manufacturing and commercialization of complex generic pharmaceuticals globally.
Scroll
View
Swipe
Play
Enabling affordable
medicines globally
Science. People. Affordable Medicines.
Synthon is a leading pharmaceutical company specialized in the development, manufacturing and commercialization of complex generic pharmaceuticals globally.
Enabling affordable
medicines globally
Science. People. Affordable Medicines.
Synthon is a leading pharmaceutical company specialized in the development, manufacturing and commercialization of complex generic pharmaceuticals globally.
Our legacy
More than three decades of developing complex generics
Founded in 1991, Synthon has been a leader in the development, manufacture and commercialization of complex generics for more than three decades. With a focus on innovation, science and intellectual property to drive differentiation, Synthon has become the leading B2B player in the generics industry.
Synthon is
The development engine for the generics industry
As a science-driven leader, we combine our three strengths: Research & Development, Manufacturing and Commercialization to make complex generic medicines available at market formation globally.
Development
Best in class generics research and developmentDevelopment is the core of what we do. Utilizing innovative technologies, scientific rigour and a data driven approach, we invest to develop safe, effective affordable medicines.
Manufacturing
Reliable, vertically integrated manufacturing networkLeveraging our global manufacturing network including API and drug product sites, we provide our customers with high reliability in terms of service levels, security of supply and product quality.
.jpeg)
Commercialization
Flexible business model to serve the needs of customers globallyOur core business is to serve as the leading Business to Business company working with partners to commercialize products globally. In select markets, we increase access to affordable medicines under the Synthon brand.
Development
Best in class generics research and developmentDevelopment is the core of what we do. Utilizing innovative technologies, scientific rigour and a data driven approach, we invest to develop safe, effective affordable medicines.
Manufacturing
Reliable, vertically integrated manufacturing networkLeveraging our global manufacturing network including API and drug product sites, we provide our customers with high reliability in terms of service levels, security of supply and product quality.
Commercialization
Flexible business model to serve the needs of customers globallyOur core business is to serve as the leading Business to Business company working with partners to commercialize products globally. In select markets, we increase access to affordable medicines under the Synthon brand.
Our leadership
Committed to success
At Synthon, we take great pride in having the best team that is purpose driven, fully engaged and committed to your success.
Worldwide presence
A global company
Through careful expansion to meet customer needs and ensure high-quality generic medicines, our company has expanded its geographical footprint to operate as a global company, with local knowledge to serve our partners.
Our updates
Read our latest news
Jun 2026Synthon Announces Strategic Expansion in Spain
Synthon, a global leader in the development and manufacturing of complex generic medicines, today announced a strategic expansion of its operations in Spain. The additional facility space is adjacent to its Sant Boi site.
May 2026Synthon receives EU grant to strengthen R&D capabilities in Blansko
Synthon has secured funding under the European Union’s Operational Programme Technologies and Applications for Competitiveness (OP TAK) to support the further expansion of its oligonucleotide development capabilities in Blansko, Czech Republic.
Apr 2026Synthon: Benelux Deal of the Year – Real Deals
BC Partners has been named winner of the ‘Benelux Deal of the Year’ award at the Real Deals Private Equity Awards 2026, recognising the successful partnership with Synthon.
The award highlights Synthon’s strong organic growth, capex‑led value creation and disciplined strategic execution, including margin improvement, commercial enhancements and international expansion achieved during BC Partners’ ownership.
Sep 2025Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.
Jun 2025Synthon Announces Investment from Goldman Sachs Alternatives
Nijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.
Jun 2026Synthon Announces Strategic Expansion in SpainSynthon, a global leader in the development and manufacturing of complex generic medicines, today announced a strategic expansion of its operations in Spain. The additional facility space is adjacent to its Sant Boi site.
May 2026Synthon receives EU grant to strengthen R&D capabilities in BlanskoSynthon has secured funding under the European Union’s Operational Programme Technologies and Applications for Competitiveness (OP TAK) to support the further expansion of its oligonucleotide development capabilities in Blansko, Czech Republic.
Apr 2026Synthon: Benelux Deal of the Year – Real DealsBC Partners has been named winner of the ‘Benelux Deal of the Year’ award at the Real Deals Private Equity Awards 2026, recognising the successful partnership with Synthon.
The award highlights Synthon’s strong organic growth, capex‑led value creation and disciplined strategic execution, including margin improvement, commercial enhancements and international expansion achieved during BC Partners’ ownership.
Sep 2025Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. marketZydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.
Jun 2025Synthon Announces Investment from Goldman Sachs AlternativesNijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.
Jun 2026Synthon Announces Strategic Expansion in SpainSynthon, a global leader in the development and manufacturing of complex generic medicines, today announced a strategic expansion of its operations in Spain. The additional facility space is adjacent to its Sant Boi site.
May 2026Synthon receives EU grant to strengthen R&D capabilities in BlanskoSynthon has secured funding under the European Union’s Operational Programme Technologies and Applications for Competitiveness (OP TAK) to support the further expansion of its oligonucleotide development capabilities in Blansko, Czech Republic.
Apr 2026Synthon: Benelux Deal of the Year – Real DealsBC Partners has been named winner of the ‘Benelux Deal of the Year’ award at the Real Deals Private Equity Awards 2026, recognising the successful partnership with Synthon.
The award highlights Synthon’s strong organic growth, capex‑led value creation and disciplined strategic execution, including margin improvement, commercial enhancements and international expansion achieved during BC Partners’ ownership.
Sep 2025Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. marketZydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.
Jun 2025Synthon Announces Investment from Goldman Sachs AlternativesNijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.
Jun 2026Synthon Announces Strategic Expansion in SpainSynthon, a global leader in the development and manufacturing of complex generic medicines, today announced a strategic expansion of its operations in Spain. The additional facility space is adjacent to its Sant Boi site.
May 2026Synthon receives EU grant to strengthen R&D capabilities in BlanskoSynthon has secured funding under the European Union’s Operational Programme Technologies and Applications for Competitiveness (OP TAK) to support the further expansion of its oligonucleotide development capabilities in Blansko, Czech Republic.
Apr 2026Synthon: Benelux Deal of the Year – Real DealsBC Partners has been named winner of the ‘Benelux Deal of the Year’ award at the Real Deals Private Equity Awards 2026, recognising the successful partnership with Synthon.
The award highlights Synthon’s strong organic growth, capex‑led value creation and disciplined strategic execution, including margin improvement, commercial enhancements and international expansion achieved during BC Partners’ ownership.
Sep 2025Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. marketZydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.
Jun 2025Synthon Announces Investment from Goldman Sachs AlternativesNijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.
Work with us
Working together for patients worldwide
Our mission is to create access to high-quality generic medicines for all patients. We believe in our trusted partnerships to achieve our goals. If you would like to discuss partnering opportunities, get in touch.